GDF10

Summary

GDF10 (growth differentiation factor 10, HGNC:4215) is a protein-coding gene on chromosome 10q11.22, encoding Growth/differentiation factor 10 (P55107). Growth factor involved in osteogenesis and adipogenesis.

This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. This promotes neural repair after stroke. Additionally, this protein may act as a tumor suppressor and reduced expression of this gene is associated with oral cancer.

Source: NCBI Gene 2662 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 87 total — 1 pathogenic
• MANE Select transcript: NM_004962

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4215
Approved symbol	GDF10
Name	growth differentiation factor 10
Location	10q11.22
Locus type	gene with protein product
Status	Approved
Aliases	BMP-3b
Ensembl gene	ENSG00000266524
Ensembl biotype	protein_coding
OMIM	601361
Entrez	2662

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000580279, ENST00000895678

RefSeq mRNA: 1 — MANE Select: NM_004962 NM_004962

CCDS: CCDS73117

Canonical transcript exons

ENST00000580279 — 3 exons

Exon	Start	End
ENSE00002699841	47309796	47310721
ENSE00002721632	47300197	47300970
ENSE00002728838	47312601	47313577

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 84.48.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5797 / max 287.0853, expressed in 389 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104829	1.5994	341
104831	0.8278	223
104828	0.0670	29
104827	0.0484	22
104830	0.0372	22

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.48	gold quality
right lung	UBERON:0002167	82.40	gold quality
upper lobe of left lung	UBERON:0008952	80.38	gold quality
tibial nerve	UBERON:0001323	79.55	gold quality
tibia	UBERON:0000979	79.04	gold quality
upper lobe of lung	UBERON:0008948	78.48	gold quality
body of pancreas	UBERON:0001150	78.39	gold quality
popliteal artery	UBERON:0002250	77.11	gold quality
tibial artery	UBERON:0007610	77.10	gold quality
lung	UBERON:0002048	76.77	gold quality
lower esophagus muscularis layer	UBERON:0035833	76.41	gold quality
lower esophagus	UBERON:0013473	76.27	gold quality
descending thoracic aorta	UBERON:0002345	75.81	gold quality
subcutaneous adipose tissue	UBERON:0002190	75.57	gold quality
aorta	UBERON:0000947	75.00	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	74.72	gold quality
right lobe of thyroid gland	UBERON:0001119	74.67	gold quality
minor salivary gland	UBERON:0001830	74.08	gold quality
calcaneal tendon	UBERON:0003701	74.04	gold quality
left lobe of thyroid gland	UBERON:0001120	73.73	gold quality
skin of hip	UBERON:0001554	73.62	gold quality
right coronary artery	UBERON:0001625	73.21	gold quality
thyroid gland	UBERON:0002046	73.13	gold quality
ascending aorta	UBERON:0001496	72.75	gold quality
thoracic aorta	UBERON:0001515	72.68	gold quality
tendon	UBERON:0000043	72.62	gold quality
left coronary artery	UBERON:0001626	72.34	gold quality
Brodmann (1909) area 10	UBERON:0013541	71.95	silver quality
caudate nucleus	UBERON:0001873	71.61	gold quality
tendon of biceps brachii	UBERON:0008188	71.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.08

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX2

miRNA regulators (miRDB)

64 targeting GDF10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-587	99.64	70.86	2611

Literature-anchored findings (GeneRIF, showing 10)

• new hypoxia-inducible and SOX9-regulated genes, Gdf10 and Chm-I. In addition, Mig6 and InhbA were induced by hypoxia, predominantly via HIF-2alpha (PMID:18077449)
• BMP3b and BMP6 genes were suppressed by DNA methylation and methylation of BMP3b is significantly frequent in Japanese malignant pleural mesotheliomas (MPMs), suggesting its pathogenic role and the ethnic difference in MPMs. (PMID:18949431)
• Study shows that GDF10 is down-regulated in patients with oral squamous cell carcinoma, and is an independent risk factor for overall survival. Its expression is regulated by TGFBR3 which shares the signaling inhibiting epithelial-mesenchymal transition. (PMID:25728212)
• GDF10 is a stroke-induced signal for axonal sprouting and functional recovery. (PMID:26502261)
• acts as a tumor suppressor in mammary epithelial cells; limits proliferation and suppresses epithelial-mesenchymal transition (PMID:31147529)
• Mesenchymal Bmp3b expression maintains skeletal muscle integrity and decreases in age-related sarcopenia. (PMID:33170806)
• Cancer-associated fibroblasts promote tumor progression by lncRNA-mediated RUNX2/GDF10 signaling in oral squamous cell carcinoma. (PMID:33657265)
• GDF10 inhibits cell proliferation and epithelial-mesenchymal transition in nasopharyngeal carcinoma by the transforming growth factor-beta/Smad and NF-kappaB pathways. (PMID:34922336)
• Single-Cell Analysis Uncovers Osteoblast Factor Growth Differentiation Factor 10 as Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation Associated with Plaque Rupture in Human Carotid Artery Disease. (PMID:35163719)
• Reduced plasma GDF10 levels are positively associated with cholesterol impairment and childhood obesity. (PMID:38245533)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gdf10b	ENSDARG00000073891
danio_rerio	gdf10a	ENSDARG00000095378
mus_musculus	Gdf10	ENSMUSG00000021943
rattus_norvegicus	Gdf10	ENSRNOG00000051993

Paralogs (31): TGFB2 (ENSG00000092969), BMP7 (ENSG00000101144), TGFB1 (ENSG00000105329), BMP5 (ENSG00000112175), BMP8B (ENSG00000116985), TGFB3 (ENSG00000119699), INHBA (ENSG00000122641), INHA (ENSG00000123999), BMP4 (ENSG00000125378), BMP2 (ENSG00000125845), GDF5 (ENSG00000125965), GDF1 (ENSG00000130283), BMP15 (ENSG00000130385), GDF15 (ENSG00000130513), GDF11 (ENSG00000135414), MSTN (ENSG00000138379), INHBE (ENSG00000139269), LEFTY2 (ENSG00000143768), GDF7 (ENSG00000143869), BMP3 (ENSG00000152785), BMP6 (ENSG00000153162), GDF6 (ENSG00000156466), NODAL (ENSG00000156574), INHBB (ENSG00000163083), BMP10 (ENSG00000163217), GDF9 (ENSG00000164404), INHBC (ENSG00000175189), BMP8A (ENSG00000183682), GDF3 (ENSG00000184344), LEFTY1 (ENSG00000243709), GDF2 (ENSG00000263761)

Protein

Protein identifiers

Growth/differentiation factor 10 — P55107 (reviewed: P55107)

Alternative names: Bone morphogenetic protein 3B, Bone-inducing protein

All UniProt accessions (1): P55107

UniProt curated annotations — full annotation on UniProt →

Function. Growth factor involved in osteogenesis and adipogenesis. Plays an inhibitory role in the process of osteoblast differentiation via SMAD2/3 pathway. Plays an inhibitory role in the process of adipogenesis.

Subunit / interactions. Homodimer or heterodimer. Can form a non-covalent complex of the mature region and the pro-region.

Subcellular location. Secreted.

Tissue specificity. Expressed in femur, brain, lung, skeletal muscle, pancreas and testis.

Similarity. Belongs to the TGF-beta family.

RefSeq proteins (1): NP_004953* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001839	TGF-b_C	Domain
IPR015615	TGF-beta-like	Family
IPR017197	BMP3/BMP3B	Family
IPR017948	TGFb_CS	Conserved_site
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF00019

UniProt features (12 total): disulfide bond 4, glycosylation site 4, signal peptide 1, propeptide 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55107-F1	67.70	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 409–477, 442, 376–443, 405–475

Glycosylation sites (4): 118, 156, 281, 469

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 125 (showing top): GOBP_HINDBRAIN_DEVELOPMENT, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_METENCEPHALON_DEVELOPMENT, STAEGE_EWING_FAMILY_TUMOR, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_RESPONSE_TO_ACID_CHEMICAL, GOBP_OSTEOBLAST_DIFFERENTIATION, MAHADEVAN_IMATINIB_RESISTANCE_DN, GOMF_GROWTH_FACTOR_ACTIVITY, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, DELYS_THYROID_CANCER_DN

GO Biological Process (13): skeletal system development (GO:0001501), osteoblast differentiation (GO:0001649), cell surface receptor protein serine/threonine kinase signaling pathway (GO:0007178), transforming growth factor beta receptor signaling pathway (GO:0007179), cerebellum development (GO:0021549), negative regulation of ossification (GO:0030279), ovulation cycle (GO:0042698), fat cell differentiation (GO:0045444), positive regulation of osteoblast differentiation (GO:0045669), response to kainic acid (GO:1904373), ossification (GO:0001503), regulation of ossification (GO:0030278), response to transforming growth factor beta (GO:0071559)

GO Molecular Function (3): cytokine activity (GO:0005125), growth factor activity (GO:0008083), protein serine/threonine kinase activator activity (GO:0043539)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ossification	3
cell differentiation	2
receptor ligand activity	2
system development	1
enzyme-linked receptor protein signaling pathway	1
cellular response to transforming growth factor beta stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
metencephalon development	1
anatomical structure development	1
regulation of ossification	1
negative regulation of multicellular organismal process	1
rhythmic process	1
multicellular organismal reproductive process	1
osteoblast differentiation	1
positive regulation of cell differentiation	1
regulation of osteoblast differentiation	1
response to amino acid	1
response to nitrogen compound	1
response to oxygen-containing compound	1
multicellular organismal process	1
regulation of multicellular organismal process	1
response to growth factor	1
protein serine/threonine kinase activity	1
protein kinase activator activity	1
external encapsulating structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1376 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GDF10	ACVR2A	P27037	661
GDF10	SMAD2	Q15796	603
GDF10	ACVR1B	P36896	594
GDF10	BMPR1A	P36894	583
GDF10	ACVR1	Q04771	563
GDF10	ACVR2B	Q13705	514
GDF10	NTN1	O95631	505
GDF10	BMP5	P22003	473
GDF10	BMP1	P13497	469
GDF10	WNT4	P56705	451
GDF10	FRMPD2	Q68DX3	443
GDF10	MATN2	O00339	423
GDF10	GPC3	P51654	399
GDF10	RASGEF1A	Q8N9B8	396
GDF10	PAEP	P09466	396

IntAct

6 interactions, top by confidence:

A	B	Type	Score
GDF10	LRP4	psi-mi:“MI:0914”(association)	0.530
IGHA1	PLG	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (10): GDF10 (Synthetic Lethality), LRP4 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), BANP (Affinity Capture-MS), ZNF507 (Affinity Capture-MS), MTHFR (Affinity Capture-MS), FBXO45 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), ZNF507 (Affinity Capture-MS), LRP4 (Affinity Capture-MS)

ESM2 similar proteins: B2RZ42, D4A6L0, E1BBQ2, J3QPP8, O02695, O62827, P01346, P01356, P06307, P06881, P09535, P12755, P12843, P15473, P16611, P17936, P20959, P22444, P22692, P24854, P47878, P49002, P49192, P49705, P53366, P55107, P55108, P56388, P80560, P97737, Q05716, Q08DX6, Q16568, Q26492, Q4RU86, Q58CS8, Q5T848, Q63475, Q68RJ9, Q6DVA0

Diamond homologs: A1C2U3, A1C2U6, A1C2U7, A1C2V0, A1C2V5, A8E7N9, G5EEL5, O08689, O14793, O18828, O18830, O18831, O18836, O35312, O42220, O42221, O42222, O46576, O61643, O95390, O95393, P09534, P12644, P12645, P17491, P18075, P20722, P20863, P22003, P22004, P22444, P23359, P27091, P27539, P35621, P43026, P43027, P43028, P43029, P48970

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	80
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1072695	NC_000010.10:g.(?48370533)(48438710_?)del	Pathogenic

SpliceAI

423 predictions. Top by Δscore:

Variant	Effect	Δscore
10:47312598:C:CC	acceptor_gain	1.0000
10:47312598:CTGC:C	acceptor_loss	1.0000
10:47312599:TCTG:T	acceptor_loss	1.0000
10:47312600:AT:A	acceptor_gain	1.0000
10:47312601:GAT:G	acceptor_gain	1.0000
10:47312602:CGAT:C	acceptor_gain	1.0000
10:47312602:CGATC:C	acceptor_gain	1.0000
10:47312603:ACGAT:A	acceptor_gain	1.0000
10:47300902:T:TA	donor_gain	0.9900
10:47300969:C:CA	donor_loss	0.9900
10:47300969:C:CC	donor_gain	0.9900
10:47300969:CC:C	donor_gain	0.9900
10:47300969:CCCAG:C	donor_gain	0.9900
10:47300970:A:AC	donor_gain	0.9900
10:47300970:AC:A	donor_gain	0.9900
10:47300971:TA:T	donor_loss	0.9900
10:47300972:TTA:T	donor_loss	0.9900
10:47300973:CTTA:C	donor_loss	0.9900
10:47300974:ACTTA:A	donor_loss	0.9900
10:47300975:TACTT:T	donor_loss	0.9900
10:47300976:CTACT:C	donor_loss	0.9900
10:47309793:C:CC	acceptor_gain	0.9900
10:47309796:CTT:C	acceptor_gain	0.9900
10:47309798:CACTT:C	acceptor_gain	0.9900
10:47310700:C:CC	donor_gain	0.9900
10:47310700:CATG:C	donor_gain	0.9900
10:47310701:A:AC	donor_gain	0.9900
10:47312589:A:T	acceptor_gain	0.9900
10:47312590:C:CT	acceptor_gain	0.9900
10:47312597:T:C	acceptor_loss	0.9900

AlphaMissense

3088 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:47310646:G:C	W390C	0.999
10:47310646:G:T	W390C	0.999
10:47310689:T:A	C405S	0.999
10:47310690:G:A	C405Y	0.999
10:47310690:G:C	C405S	0.999
10:47310691:C:G	C405W	0.999
10:47310701:T:C	C409R	0.999
10:47310702:G:A	C409Y	0.999
10:47310703:T:G	C409W	0.999
10:47310707:T:C	F411L	0.999
10:47310708:T:G	F411C	0.999
10:47310709:C:A	F411L	0.999
10:47310709:C:G	F411L	0.999
10:47312629:T:A	I425N	0.999
10:47312682:T:A	C443S	0.999
10:47312682:T:C	C443R	0.999
10:47312683:G:A	C443Y	0.999
10:47312683:G:C	C443S	0.999
10:47312684:T:G	C443W	0.999
10:47310602:T:A	C376S	0.998
10:47310602:T:C	C376R	0.998
10:47310603:G:A	C376Y	0.998
10:47310603:G:C	C376S	0.998
10:47310604:C:G	C376W	0.998
10:47310630:T:G	F385C	0.998
10:47310644:T:A	W390R	0.998
10:47310644:T:C	W390R	0.998
10:47310655:G:C	W393C	0.998
10:47310655:G:T	W393C	0.998
10:47310689:T:C	C405R	0.998

dbSNP variants (sampled 300 via entrez): RS1000089486 (10:47305289 G>A), RS1000095104 (10:47311918 G>A,C,T), RS1000479269 (10:47310074 C>G), RS1000930983 (10:47298563 G>T), RS1000993495 (10:47304327 G>A,C,T), RS1001285980 (10:47298748 C>G,T), RS1001497488 (10:47304106 G>A), RS1001549648 (10:47310317 A>C,G), RS1002046582 (10:47302793 A>G), RS1002149628 (10:47309164 T>C), RS1002656156 (10:47313165 G>A), RS1002999324 (10:47301562 C>T), RS1003067464 (10:47301277 A>T), RS1003558232 (10:47307738 G>A), RS1003658206 (10:47312147 C>T)

Disease associations

OMIM: gene MIM:601361 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004639_14	Prudent dietary pattern	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008111	diet measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
trichostatin A	increases expression	2
Tretinoin	increases expression	2
bisphenol A	affects expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	increases expression	1
Panobinostat	affects cotreatment, increases expression	1
Arsenic	affects expression	1
Benzo(a)pyrene	decreases methylation	1
Dexamethasone	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Nickel	decreases expression	1
Phenylmercuric Acetate	increases expression, affects cotreatment	1
Plant Extracts	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tetradecanoylphorbol Acetate	affects cotreatment, affects expression	1
Triclosan	decreases expression	1
Zinc	affects cotreatment, affects expression	1
8-Bromo Cyclic Adenosine Monophosphate	increases expression	1
Levonorgestrel	affects cotreatment, decreases expression	1
Medroxyprogesterone Acetate	decreases expression	1
Antirheumatic Agents	increases expression	1
Genistein	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer